"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

At the 66th American Society of Hematology Annual Meeting, a plethora of companies presented clinical trial data highlighting ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data ...

The aberrant activation of B cells plays a central role in the pathogenesis of various autoimmune diseases and B-cell ... signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...

Sanofi-Aventis Groupe announced positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or ...

including mechanism of action and relevant disease models, from two pipeline programs: NX-5948 and GS-6791. NX-5948 is Nurix’s proprietary, orally available, brain penetrant Bruton’s tyrosine ...